Evidence map›Paper›PMID 26840761›Full record

ArticleMolecular carcinogenesis2016

Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone-rich Kava fraction.

Su-Ni Tang, Jinhui Zhang, Peixin Jiang, Palika Datta, Pablo Leitzman, M Gerard O'Sullivan, Cheng Jiang, Chengguo Xing, Junxuan Lü

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Opportunities and Challenges of Kava in Lung Cancer Prevention.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Interception Targets ofCancer prevention research (Philadelphia, Pa.) · 2021
    Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Su-Ni TangDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, Texas.
Jinhui ZhangDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, Texas.
Peixin JiangDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, Texas.
Palika DattaDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, Texas.
Pablo LeitzmanDepartment of Medicinal Chemistry, University of Minnesota College of Pharmacy, Minneapolis, Minnesota.
M Gerard O'SullivanDepartment of Veterinary Population Medicine and University of Minnesota Masonic Cancer Center Comparative Pathology Shared Resource, College of Veterinary Medicine, St. Paul, Minnesota.
Cheng JiangDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, Texas.
Chengguo XingDepartment of Medicinal Chemistry, University of Minnesota College of Pharmacy, Minneapolis, Minnesota.
Junxuan LüDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, Texas.
Texas Tech University · USUniversity of Minnesota · USTexas Tech University Health Sciences Center · US

Funding

Mechanisms of prostate cancer prevention by Korean AngelicaR01AT007395 · NCCIH · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI LU, JUNXUAN · 2012 to 2016
$2.2M
Dihydromethysticin (DHM) for Lung Cancer ChemopreventionR01CA193278 · NCI · UNIVERSITY OF MINNESOTA · PI XING, CHENGGUO · 2015 to 2019
$1.7M
Prostate cancer chemoprevention by penta-galloyl-glucoseR01CA136953 · NCI · UNIVERSITY OF MINNESOTA · PI LU, JUNXUAN · 2009 to 2014
$1.5M
Developing a Post-carcinogen Lung Cancer Chemopreventive AgentR01CA142649 · NCI · UNIVERSITY OF MINNESOTA · PI XING, CHENGGUO · 2010 to 2014
$1.0M
NCCIH NIH HHS R01 AT007395NCI NIH HHS R01 CA136953NCI NIH HHS R01 CA142649NCI NIH HHS R01 CA193278
6 · The paper itself

Abstract

Kava (Piper methysticum Forster) extract and its major kavalactones have been shown to block chemically induced lung tumor initiation in mouse models. Here we evaluated the chemopreventive effect of a kavalactone-rich Kava fraction B (KFB), free of flavokavains, on carcinogenesis in a transgenic adenocarcinoma of mouse prostate (TRAMP) model and characterized the prostate gene expression signatures. Male C57BL/6 TRAMP mice were fed AIN93M diet with or without 0.4% KFB from 8 wk of age. Mice were euthanized at 16 or 28 wk. The growth of the dorsolateral prostate (DLP) lobes in KFB-treated TRAMP mice was inhibited by 66% and 58% at the respective endpoint. Anterior and ventral prostate lobes in KFB-treated TRAMP mice were suppressed by 40% and 49% at 28 wk, respectively. KFB consumption decreased cell proliferation biomarker Ki-67 and epithelial lesion severity in TRAMP DLP, without detectable apoptosis enhancement. Real time qRT-PCR detection of mRNA from DLP at 28 wk showed decreased expression of cell cycle regulatory genes congruent with Ki-67 suppression. Microarray profiling of DLP mRNA indicated that "oncogene-like" genes related to angiogenesis and cell proliferation were suppressed by KFB but tumor suppressor, immunity, muscle/neuro, and metabolism-related genes were upregulated by KFB in both TRAMP and WT DLP. TRAMP mice fed KFB diet developed lower incidence of neuroendocrine carcinomas (NECa) (2 out of 14 mice) than those fed the basal diet (8 out of 14 mice, χ

Indexed as

AdenocarcinomaAnimalsAntineoplastic Agents, PhytogenicCarcinogenesisFemaleGene Expression Regulation, NeoplasticKavaLactonesMaleMiceMice, Inbred C57BLProstateProstatic NeoplasmsTranscriptomeTransgenesAntineoplastic Agents, PhytogenicLactonesKava kavalactone rich fractionneuroendocrine carcinomaprostate epithelial lesionsTRAMP

Identifiers

PMID26840761
PMCPMC6518389
OpenAlexW2256650448

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.